Loading clinical trials...
Loading clinical trials...
Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours Are Epidermal Growth Factor Receptor-2 (HER 2) Amplified or Co-expressing Epidermal Growth Factor Receptor-1 (HER-1) and HER-2.
Conditions
Interventions
ASLAN001
Locations
2
South Korea
Seoul National University Hospital
Bundang, Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Start Date
March 1, 2012
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
January 14, 2015
NCT07072728
NCT06885697
NCT06630130
NCT07035587
NCT05264896
NCT01649271
Lead Sponsor
ASLAN Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions